Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

11 Jul 2016 07:01

RNS Number : 7470D
Eland Oil & Gas PLC
11 July 2016
 

11 July 2016

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

Directorate Change

 

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, today announces the appointment of Henry Obi to the Board as a Non-Executive Director representing Helios Natural Resources a significant shareholder in Eland. Henry will replace Richard Norris who has been Helios Natural Resources' representative on the Board since September 2014. The Board thanks Richard for his valuable contribution and wishes him well for the future.

 

Henry Obi has over 15 years' experience in private equity sector and is currently a Partner and Chief Operating Officer at Helios Investment Partners LLP ("Helios") where he responsible for its operations and serves on Helios' Equity and Credit Investment Committees. Prior to joining Helios in 2006, Henry was a Partner at Aureos Advisers Limited where he was responsible for monitoring the performance of the firm's funds in Africa and Central America and their compliance with investment policy. Prior to Aureos, Henry worked for Actis, CDC Group Plc and Dynegy, a US energy trader.

 

Henry holds a BSc. Architecture and MSc. Architecture from University of Nigeria, a B.Arch. from University of Nottingham and an MBA in Finance from the London Business School. He sits on the Boards of Maris Capital Limited and the Africa Venture Capital Association. He also served as Chairman of the Africa Regional Advisory Council of Emerging Market Private Equity Association. He received Private Equity Africa's Outstanding Leadership Award in 2014 for his commitment to advancing the cause of private equity in Africa.

 

 

Henry Awele Obi's (age 53) current directorships and partnerships are as follows:

 

Advance American Style Inc.

African Private Equity & Venture Capital Association

Helios Credit Genpar, Limited

Helios Investment Partners, LLP

HIP Africa Ltd.

HIP Equity I, L.P.

HIP Equity II. L.P.

HIP Equity III, L.P.

Interswitch Limited

Maris Capital Limited

 

 

Mr Obi's directorships in the last five years are as follows

 

Royal Exchange Microfinance Bank Limited

 

Henry Obi indirectly holds 10,043 voting ordinary shares in Eland through HIP Equity II, L.P. ("HIP Equity") (representing 0.01% of the current voting ordinary share capital of the Company) and a further 1,150 non-voting ordinary shares indirectly through Helios Natural Resources Ltd whose only asset is shares in Eland. Any monetisation of the indirect stake is at the sole discretion of Helios Natural Resources Ltd.

 

Helios Natural Resources Limited holds 54,963,815 voting ordinary shares in the Company, including those held on behalf of Mr Obi as described above, representing 29.5% of the current voting ordinary share capital of the Company. Helios Natural Resources Ltd also hold 6,296,815 non-voting ordinary shares, including those held on behalf of Mr Obi.

 

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Olivier Serra, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7523 8000)

Henry Fitzgerald O'Connor

Nilesh Patel

 

Panmure Gordon (UK) Limited (+44 (0)20 7886 2500)

Adam James / Atholl Tweedie

Tom Salvesen

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg / Georgia Mann

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKMGMNLGLGVZM
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.